Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

7.400 +0.100 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Largest Phase 3 Clinical Trial on Psilocybin Gets Underway
Via Investor Brand Network
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud 
Via Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for... 
Via Benzinga
Expert Ratings for Compass Pathways
Via Benzinga
Compass Pathways: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Compass Pathways
Via Benzinga
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support... 
Via Benzinga
Link Between Cancer And Psilocybin: Research On This Palliative Promise
The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way. 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent... 
Via Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated... 
Via Benzinga
Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript
CMPS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
Another piece of the regulatory puzzle fell into place, but there are plenty more. 
Via The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS... 
Via Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved 
From COMPASS Pathways
Via GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Atai's stock is hurting, but its pipeline is still packed with promising programs. 
Via The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
Via Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published... 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.